Subgroup analyses comparing patients with T2DM under 60 years of age who received SGLT2 inhibitors with their counterparts aged 60 years and older demonstrated a significantly lower incidence (p = 0.0008) and severity (p = 0.0011) of DED in the younger patients (Table 4). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.